U.S. market Open. Closes in 6 hours

AKRO | Akero Therapeutics, Inc. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
RevenueN/AN/AN/AN/AN/AN/A
Cost of Revenue29.00K260.00K244.00K213.00KN/AN/A
Gross Profit-29.00K-260.00K-244.00K-213.00KN/AN/A
Operating Expenses172.87M115.16M100.89M80.15M45.65M13.78M
Selling, General & Admin31.07M29.87M19.13M15.24M8.61M1.90M
Research & Development141.80M85.28M81.76M64.92M37.05M11.88M
Other Operating ExpensesN/A3.86M109.00K947.00K1.90M-67.94M
Operating Income-172.87M-115.16M-100.89M-80.15M-45.65M-13.78M
Other Expenses / Income21.11M3.12M109.00K947.00K1.90M-67.94M
Before Tax Income-151.76M-112.03M-100.78M-79.21M-43.76M-81.71M
Income Tax ExpensesN/A-3.12M-41.00K-17.00K24.00KN/A
Net Income-151.76M-108.91M-100.74M-79.19M-43.76M-81.71M
Interest Expenses3.10M739.00KN/AN/AN/AN/A
Basic Shares Outstanding52.57M38.98M34.83M31.46M15.07M21.22M
Diluted Shares Outstanding52.57M38.98M34.83M31.46M15.07M21.22M
EBITDA-172.84M-111.29M-100.89M-80.15M-45.65M-81.71M
EBITDA Margin0.00%0.00%0.00%0.00%0.00%0.00%
EBIT-148.66M-111.29M-100.78M-79.21M-43.73M-81.71M
EBIT Margin0.00%0.00%0.00%0.00%0.00%0.00%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙